Global Aspergillosis Treatment Market Report 2023-2030 with Competitive Analysis of Pfizer, Merck, F2G, Novartis, Astellas, Bayer, Mayne Pharma, & PULMATRiX

DUBLIN, Oct. 25, 2023 /PRNewswire/ -- The "Aspergillosis Treatment Market Size, Share & Trends Analysis Report By Type (Allergic, Chronic, Invasive), By Drug Class (Antifungal), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030" report has been added to  ResearchAndMarkets.com's offering.

The global aspergillosis treatment market size is expected to reach USD 5.79 billion by 2030, registering a CAGR of 3.99% from 2023 to 2030

The rising incidence of aspergillosis infections, particularly among immunocompromised individuals, is driving demand for innovative treatment approaches. Advances in medical technology and drug development have led to more targeted and effective therapies, improving patient outcomes and treatment efficacy.

Increased awareness and diagnostic capabilities have contributed to early detection and prompt treatment initiation, further boosting the demand for various drugs. The current treatment paradigm relies on conventional antifungal drugs, including azoles, antibiotics, and corticosteroids.

Prominent companies such as F2G, TFF Pharmaceuticals, Scynexis, and Pulmocide are introducing innovative therapeutic strategies that could revolutionize the treatment of Invasive Aspergillosis, challenging established pharmaceutical leaders.

Ongoing efforts in the field focus on innovative strategies to enhance Aspergillosis management. For example, in April 2022, Pulmatrix announced the restoration of complete rights to its portfolio of narrow-spectrum kinase inhibitors, including PUR1800, following the termination of a licensing agreement with Johnson & Johnson's Enterprise Innovation.

Aspergillosis Treatment Market Report Highlights

• Based on type, the allergic segment dominated in 2022, driven by higher prevalence and milder disease presentation in conditions like allergic bronchopulmonary aspergillosis (ABPA).
• The antifungal drug segment held the largest revenue share in 2022 among drug classes, owing to their effectiveness against aspergillosis infections.
• Oral drugs were the preferred route of administration in 2022 due to convenience and patient-friendly administration.
• Hospital pharmacies played a pivotal role, with a 47.59% share in 2022, ensuring effective delivery and accessibility of aspergillosis treatments.
• North America led the market in 2022, benefiting from advanced healthcare infrastructure, dynamic research and development (R&D) efforts, and access to cutting-edge medical technologies.

Company Profiles

• Pfizer, Inc
• Merck & Co
• F2G
• Novartis AG;
• Astellas Pharma Inc
• Bayer AG
• Mayne Pharma Group Limited
• PULMATRiX

Key Topics Covered:

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.5. Research Methodology

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Increasing Prevalence of Aspergillosis
3.4.2. Advancements in Medical Research
3.4.3. Awareness and Diagnosis Improvement
3.5. Market Restraint Analysis
3.5.1. Limited Treatment Options
3.5.2. High Treatment Costs
3.6. Industry Analysis Tools
3.6.1. Porter's Five Forces Analysis
3.6.2. PESTEL Analysis
3.6.3. COVID-19 Impact Analysis

Chapter 4. Aspergillosis Treatment Market: By Type Segment Analysis
4.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
4.2. Allergic Aspergillosis
4.2.1. Allergic Aspergillosis Market, 2018 - 2030 (USD Million)
4.3. Chronic Aspergillosis
4.4. Invasive Aspergillosis

Chapter 5. Aspergillosis Treatment Market: Drug Class Segment Analysis
5.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
5.2. Antifungal Drugs
5.2.1. Antifungal Drugs Market, 2018 - 2030 (USD Million)
5.2.1.1. Azoles
5.2.1.2. Echinocandins
5.2.1.3. Polyenes
5.2.1.4. Allylamines
5.2.1.5. Others
5.3. Others

Chapter 6. Aspergillosis Treatment Market: Route of Administration Segment Analysis
6.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
6.2. Oral Drugs
6.2.1. Oral Drugs Market, 2018 - 2030 (USD Million)
6.3. Ointments
6.4. Powders
6.5. Others

Chapter 7. Aspergillosis Treatment Market: By Distribution Channel Segment Analysis
7.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
7.2. Hospital Pharmacy
7.2.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
7.3. Retail Pharmacy
7.4. Others

Chapter 8. Regional Business Analysis
8.1. Aspergillosis Treatment Market Share By Region, 2022 & 2030

Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.3. Company Market Share Analysis, 2022
9.4. Company Profiles/Listing
9.4.1. Overview
9.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.3. Product Benchmarking
9.4.4. Strategic Initiatives

For more information about this report visit https://www.researchandmarkets.com/r/k20sd2

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets